Under construction – not a live service
Sign in
Taking people in United StatesPhase 1

Tests JNJ-90301900 with chemoradiation for advanced head and neck cancer

Tests an injected drug with chemotherapy and radiation in adults with head and neck cancer.

Key facts

Who runs it
Johnson & Johnson Enterprise Innovation Inc.
Where
Atlanta, Birmingham, Boston, Chapel Hill, Duarte, Jacksonville, La Jolla, Philadelphia, Tampa, and The Bronx, United StatesSee the 10 sitesAlso in 3 other countries, 15 sites
Registry title
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Status
Recruiting
Phase
Phase 1
People taking part
45 people, planned
Started
26 Jan 2026
Expected to end
14 Jul 2028
Type of study
Interventional
Treatments tested
  • JNJ-90301900
  • Cisplatin
  • Intensity Modulated Radiation Therapy (IMRT)
  • Carboplatin
  • Paclitaxel
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with locally advanced head and neck squamous cell cancer who will have chemotherapy and radiation, with JNJ-90301900 injected into the tumor.

Age
18 to 74 years
Sex
All sexes can join.
Disease stage
Squamous cell cancer of the oral cavity, oropharynx (p16 negative), hypopharynx or supraglottic larynx. Stage III, IVA or IVB. At least 1 target lesion (primary tumor or involved lymph node). ECOG performance status 0 or 1.
Earlier treatment
A candidate for definitive concurrent chemoradiation therapy. Platinum-based chemotherapy must be possible.
Biomarker or test result
Oropharynx cancer must be p16 negative.

Main reasons for not taking part

  • Tumor starting in the nasopharynx, sinuses, salivary glands, thyroid, parathyroid, skin or unknown site
  • Non-squamous cancer type
  • Stage 0, I, II or IVC, cancer that came back in the same area, or a second primary head and neck cancer within 2 months
  • Cannot receive platinum-based chemotherapy
  • Known or suspected allergy to JNJ-90301900 or its ingredients

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
  • Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines
  • A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines
  • Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1

Who cannot take part

  • Ineligible to receive platinum-based chemotherapy
  • Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients
  • Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site
  • Non-squamous histology
  • Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 74 years old?

Where in United States

Also in 3 other countries, 15 sites

  • Emory UniversityAtlanta, United StatesTaking people
  • University of Alabama at BirminghamBirmingham, United StatesTaking people
  • Boston Medical CenterBoston, United StatesTaking people
  • University of North Carolina at Chapel HillChapel Hill, United StatesTaking people
  • City of HopeDuarte, United StatesTaking people
  • Mayo ClinicJacksonville, United StatesTaking people
  • University of California at San Diego - Moores Cancer CenterLa Jolla, United StatesNo longer taking part
  • University of PennsylvaniaPhiladelphia, United StatesTaking people
  • Moffit Cancer CenterTampa, United StatesTaking people
  • Montefiore Medical CenterThe Bronx, United StatesTaking people

About the trial

What the trial wants to find out

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

The group in the trial

  • JNJ-90301900 + Concurrent Chemoradiation Therapy (cCRT)Treatment being tested

    Participants will receive JNJ-90301900 administered intratumorally and/or intranodally, in combination with concurrent chemoradiation therapy (cCRT) consisting of platinum based chemotherapy (cisplatin or carboplatin/paclitaxel) and intensity-modulated radiation therapy (IMRT). Post-treatment follow-up will continue until the end of study (EOS), radiographic disease progression, study discontinuation, or study completion, whichever occurs first.

    Treatment: JNJ-90301900, Cisplatin, Intensity Modulated Radiation Therapy (IMRT), Carboplatin, and Paclitaxel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Plain-language title
Tests JNJ-90301900 with chemoradiation for advanced head and neck cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07219212, who can take part
Record updated
3 November 2026